Electronic nudge aims to close the gap in heart failure treatment

NCT ID NCT05433220

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study tests whether an electronic alert in a patient's medical record can prompt doctors to prescribe guideline-recommended heart failure medications that are not yet being used. The trial includes 5,000 adults with heart failure and a reduced ejection fraction (≤40%) seen at Inova clinics or hospitals. Half of the doctors will receive the alert when they open a patient's chart; the other half will continue with usual care. The goal is to see if the alert increases the number of patients on appropriate medications within 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Best practice advisory alert via electronic health record
What this could lead to
If effective, this alert system could help more heart failure patients receive life-saving medications, potentially reducing hospitalizations and deaths.
What could go wrong
The alert may not change prescribing habits, or doctors might ignore it. The study only measures short-term outcomes (30 days), so long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Inova Health System

    RECRUITING

    Falls Church, Virginia, 22042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.